Law360 (December 15, 2020, 5:58 PM EST) — The Trump administration is facing more litigation challenging a rule that links Medicare reimbursement for dozens of drugs to lower prices paid in other countries, with an oncology practice advocacy group and Regeneron Pharmaceuticals Inc. launching new lawsuits.
The Community Oncology Alliance and Regeneron both filed lawsuits Friday in Washington, D.C., and New York federal court, respectively, seeking to block the so-called most-favored-nation model for pricing Medicare Part B drugs. Both suits argue that the rule was finalized without the proper notice and public comment period as required by the Administrative Procedure Act.
The rule would “force oncologists practicing in community…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
